Following-up of a four-dose daclizumab induction therapy without calcineurin inhibitors in a liver transplantation recipient with severe renal dysfunction: a case report.
BACKGROUND
There is debate on the dose schedule and pharmacokinetics of daclizumab in liver transplant recipients.


METHODS
A four-dose course of daclizumab was administered to a patient with severe renal dysfunction. Calcineurin inhibitor therapy initiation was delayed to 86 days posttransplantation.


RESULTS
The patient is well as 480 days after transplantation. No rejection was observed.


CONCLUSIONS
The result suggested the efficacy of our dose schedule, but it will be necessary to confirm it with further pharmacokinetic studies and more cases.
Zhang
Y
Y
Liver Transplantation Division, West China Hospital, West China Medical School of Sichuan University, Chengdu, Sichuan, China.
Wen
T
T
Yan
L
L
Chen
Z
Z
Li
B
B
Zeng
Y
Y
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001002:Anuria; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D065095:Calcineurin Inhibitors; D003404:Creatinine / Q000097:blood; D000077561:Daclizumab; D006084:Graft Rejection / Q000188:drug therapy; D019698:Hepatitis C, Chronic / Q000601:surgery*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000139:chemically induced; D007677:Kidney Function Tests; D008111:Liver Function Tests; D016031:Liver Transplantation / Q000009:adverse effects / Q000276:immunology*; D008297:Male
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D065095:Calcineurin Inhibitors; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D003404:Creatinine; D000077561:Daclizumab; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D001663:Bilirubin